Skip to main content
. 2003 Nov 3;140(7):1320–1330. doi: 10.1038/sj.bjp.0705560

Figure 3.

Figure 3

Effect of VT1 and VT2 on ERK activity in human monocytes. Human monocytes were treated with VT1 or VT2 (both 3 ng ml−1) for the times indicated (a and b) or with increasing concentrations of either VT1 or VT2 for 30 min (e and f). Whole-cell extracts were blotted for phospho-ERK (a, b, e–g) or ERK (c) as outlined in the Methods section (n=3). Values obtained in (a and b) were quantified by scanning densitometry and the mean±s.d. of each value is represented in (d).